Acetato di Enfuvirtide (T-20)
Alias:Fuzeon
Sequenza:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu- Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Cas n. : 159519-65-0
Formula molecolare : C204H301N51O64
Peso molecolare : 4492
Purezza (HPLC) : 98.0%min.
Aspetto esteriore : Solido amorfo da bianco a biancastro
Singola impurità (HPLC) : 0.5%max
Composizione di amminoacidi : ±10% del teorico
Contenuto peptidico (N%) : ≥80,0%
Contenuto di acqua (Karl Fischer) : ≤8,0%
Contenuto di trifluoroacetato(HPC) : ≤12,0%
SM (ESI) : Coerente
Bilancio di massa : 95.0~105,0%
Grado : Grado farmaceutico
Magazzinaggio: Chiuso, sotto 2 ~ 8 ℃ conservazione
Utilizzo : Opzione di trattamento per i pazienti affetti da HIV/AIDS.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtide (LOCANDA) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
